ABVX:EPA
Abivax SA
77,65 €
0,00%
(0,00) 1D
5 қар., 17:35:35 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Mkt. cap
6,70 млрд
Avg. vol.
111,44 м.
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Mkt. cap
6,70 млрд
Avg. vol.
111,44 м.
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
Yahoo Finance
·
1 сағат бұрын
Nasdaq Stock Market Correction: 3 Words From Warren Buffett To Remember RIght Now
Benzinga
·
34 минут бұрын
Nasdaq Tumbles 5.5% as AI Stocks Crater: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme
Investing.com
·
1 сағат бұрын
Nasdaq Volatility Shock Warns Against Buying Too Early
The Motley Fool
·
4 сағат бұрын
The Nasdaq Plunges 5%. What the Data Center Crash Means for Investors
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 ж. 04 жел.
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com